ValuEngine upgraded shares of Asterias Biotherapeutics Inc (NYSEMKT:AST) from a sell rating to a hold rating in a research note published on Tuesday, August 29th.
Separately, HC Wainwright reissued a buy rating on shares of Asterias Biotherapeutics in a research report on Wednesday, August 16th.
Asterias Biotherapeutics (NYSEMKT AST) traded up 3.08% during mid-day trading on Tuesday, reaching $3.35. The company’s stock had a trading volume of 37,285 shares. Asterias Biotherapeutics has a 52-week low of $2.83 and a 52-week high of $5.80. The firm has a 50 day moving average price of $3.34 and a 200 day moving average price of $3.34. The company’s market cap is $167.43 million.
TRADEMARK VIOLATION WARNING: “Asterias Biotherapeutics Inc (AST) Upgraded to “Hold” at ValuEngine” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/09/13/asterias-biotherapeutics-inc-ast-upgraded-at-valuengine.html.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.